Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 5/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 4/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531518 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531344 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL532586 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531329 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531606 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL13905492 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL17366579 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL10086303 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL13905501 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL10260659 | 0.91 | CETP (0.43) | CETPNR1I2SCN5ATACR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11141410-B2 | Oxazolidinones as taro inhibitors | MERCK SHARP & DOHME CORP (US) | 2021-10-12 | — | — | US | disclosed |
| US-9901913-B2 | Catalyst and method for producing optically active anti-1,2-nitroalkanol compound | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2018-02-27 | — | — | US | disclosed |
| EP-2632269-B1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONES AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-1973889-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-1983966-B1 | POLYMER FORMULATIONS OF CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2009027785-A2 | 1, 3-OXAZOLE DERIVATIVES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141410-B2 | Oxazolidinones as taro inhibitors | OXA1L, DDO, ALPI | CETP 2701/4885NR1I2 19/4885SCN5A 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.